Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
KSBI$81.550.00(0.00%)KS Bancorp, Inc. (KSBI) Reports Strong Growth in Assets, Loans, Deposits and Equity for the Third Quarter of 2026[3:00:00 PM ET]CFFN$8.53+0.09(+1.01%)CAPITOL FEDERAL FINANCIAL, INC.® ANNOUNCES QUARTERLY DIVIDEND AND STOCK BUYBACK UPDATE Capitol Federal Financial, Inc. (NASDAQ: CFFN) (the "Company") announced today that its Board of Directors has declared a quarterly cash dividend of...[2:54:00 PM ET]ETN$385.15+13.22(+3.56%)Eaton declares quarterly dividend payable November 27, 2026[2:47:00 PM ET]AZN$170.30-1.76(-1.02%)Breast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship Research[2:40:00 PM ET]ONB$24.96-0.07(-0.26%)Old National Chairman and CEO Jim Ryan Named Chair-Elect of the American Bankers Association[2:07:00 PM ET]BCRD$5.530.00(0.00%)BlueOne Technologies Announces Enhance Global Remittance Platform[2:04:41 PM ET]CWK$12.14+0.24(+2.02%)Cushman & Wakefield Arranges $130 Million Sale of Seasons of Traverse Mountain in Lehi, Utah[2:01:00 PM ET]CTAS$214.82-11.11(-4.92%)Cintas Corporation Announces Quarterly Cash Dividend[2:00:00 PM ET]QNBC$46.68+0.67(+1.47%)QNB Corp. Reports Third Quarter 2026 Results[1:59:23 PM ET]CNXC$31.13-0.88(-2.76%)Concentrix Breaks the Language Barrier with Live Voice Translation[1:55:00 PM ET]CEG$259.38+6.90(+2.73%)Constellation Secures Conditional DOE Loan Commitment of up to $5 Billion to Expand Nuclear Output[1:35:00 PM ET]

ZBIO · NASDAQ

Zenas BioPharma, Inc.

$27.62 +0.41 (+1.51%)

Company overview

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$1.8B
Employees
130
Headquarters
Waltham, MA
Website
zenasbio.com
CEO
Leon Oliver Moulder Jr.
Listed
September 13, 2024
P/E
-3.03
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$48M
Operating income
-$423M
EBITDA
-$414M
Net income
-$425M
EPS
-$9.10
Total assets
$748M
Total debt
$352M
Earnings yield
-33.03%

Price chart

15.7020.4725.2329.9934.76
ZBIO 1D NASDAQ O27.18H28.18L26.68C27.24+0.37 (+1.38%)Vol371.65K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
ZBIOZenas BioPharma, Inc. Stock news Zenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development Transcript Seeking Alpha
ZBIOZenas BioPharma, Inc. Stock news Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know Zacks Investment Research
ZBIOZenas BioPharma, Inc. Press release Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
ZBIOZenas BioPharma, Inc. Press release Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease GlobeNewswire
ZBIOZenas BioPharma, Inc. Stock news Zenas BioPharma, Inc. (ZBIO) – What Are Analysts Thinking About This Stock? Defense World
ZBIOZenas BioPharma, Inc. Press release Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026 GlobeNewsWire
ZBIOZenas BioPharma, Inc. Press release Zenas BioPharma to Host Virtual R&D Event GlobeNewsWire
ZBIOZenas BioPharma, Inc. Stock news Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve Seeking Alpha
ZBIOZenas BioPharma, Inc. Stock news Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript Seeking Alpha
ZBIOZenas BioPharma, Inc. Press release Zenas BioPharma Announces Upcoming Presentations of GlobeNewswire
ZBIOZenas BioPharma, Inc. Press release Zenas BioPharma Announces Inducement Grants Under Nasdaq GlobeNewswire
ZBIOZenas BioPharma, Inc. Stock news Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
ZBIOZenas BioPharma, Inc. Stock news Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Seeking Alpha
ZBIOZenas BioPharma, Inc. Press release Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event GlobeNewswire
ZBIOZenas BioPharma, Inc. Press release Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences GlobeNewswire
ZBIOZenas BioPharma, Inc. Press release Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update GlobeNewsWire
ZBIOZenas BioPharma, Inc. Stock news Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medici. Globe News Wire
ZBIOZenas BioPharma, Inc. Press release Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medici. GlobeNewsWire
ZBIOZenas BioPharma, Inc. Stock news Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD Globe News Wire
ZBIOZenas BioPharma, Inc. Press release Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD GlobeNewsWire
See more
FAQ

Questions about Zenas BioPharma, Inc.

What does Zenas BioPharma, Inc. do?
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
What is ZBIO's market cap?
Zenas BioPharma, Inc. (ZBIO) is a listed stock with a live quote. The latest market cap on this page is $1.8B.
Where is Zenas BioPharma, Inc. headquartered?
Zenas BioPharma, Inc. is headquartered in Waltham, MA.
How do I get ZBIO news from the API?
Call GET /v1/news?tickers=ZBIO. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does ZBIO news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ZBIO, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the ZBIO price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs